Top

Published in:

01-12-2010

Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families

Authors: Szilvia Solyom, Katri Pylkäs, Robert Winqvist

Published in: Familial Cancer | Issue 4/2010

Abstract

In search for susceptibility genes that could explain an additional portion of familial breast cancer clustering in Finland, we set out to evaluate the presence of large genomic rearrangements in two candidate genes, BRIP1 and CHK1. BRIP1 is a BRCA1 associated protein that is mutated in a fraction of familial breast cancer and Fanconi anemia cases. To date, the role of large BRIP1 deletions in breast cancer susceptibility is not well-characterized. CHK1 is a critical maintainer of cell cycle checkpoints and genomic stability, and is also involved in the BRCA1 and FA protein signalling pathways. Although CHK1 is a very important protein for cell cycle and DNA integrity maintenance control, no mutations in this gene has yet been associated with predisposition to cancer. For the present study, blood DNA from affected index persons of 111 Northern Finnish breast cancer families was assessed for possible constitutional exonic deletions or amplifications in the BRIP1 and CHK1 genes by using the multiplex ligation-dependent probe amplification method. Our results showed that exonic deletions or amplifications affecting the BRIP1 and CHK1 genes seem not to contribute to hereditary breast cancer susceptibility in the Finnish population. To our knowledge, this is the first attempt to determine the existence of large CHK1 deletions in familial breast cancer or in any disease with a hereditary background.

Group AnglianBreastCancerStudy (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308CrossRef

Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093CrossRefPubMed

Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121CrossRefPubMed

Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22CrossRefPubMed

Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339–2347CrossRefPubMed

Cantor SB, Bell DW, Ganesan S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149–160CrossRefPubMed

Cantor S, Drapkin R, Zhang F et al (2004) The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci 101:2357–2362CrossRefPubMed

Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241CrossRefPubMed

Levitus M, Waisfisz Q, Godthelp BC et al (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37:934–935CrossRefPubMed

10.

Levran O, Attwooll C, Henry RT et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37:931–933CrossRefPubMed

11.

Litman R, Peng M, Jin Z et al (2005) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255–265CrossRefPubMed

12.

Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci 106:7155–7160CrossRefPubMed

13.

Zhang F, Fan Q, Ren K et al (2009) PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7:1110–1118CrossRefPubMed

14.

Pylkäs K, Erkko H, Nikkilä J et al (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 8:14CrossRef

15.

Karppinen SM, Vuosku J, Heikkinen K et al (2003) No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer 39:366–371CrossRefPubMed

16.

Vahteristo P, Yliannala K, Tamminen A et al (2006) BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 6:19CrossRefPubMed

17.

Yarden RI, Pardo-Reoyo S, Sgagias M et al (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285–289CrossRefPubMed

18.

Ting NS, Lee WH (2004) The DNA double-strand break response pathway: becoming more BRCAish than ever. DNA Repair 3:935–944CrossRefPubMed

19.

Bahassi EM, Ovesen JL, Riesenberg AL et al (2008) The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27:3977–3985CrossRefPubMed

20.

Wang X, Kennedy RD, Ray K et al (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 27:3098–3108CrossRefPubMed

21.

Zhi G, Wilson JB, Chen X et al (2009) Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer Res 69:8775–8783CrossRefPubMed

22.

Guervilly JH, Mace-Aime G, Rosselli F (2008) Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia. Hum Mol Genet 17:679–689CrossRefPubMed

23.

Stracker TH, Usui T, Petrini JH (2009) Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair 8:1047–1054CrossRefPubMed

24.

Collis SJ, Barber LJ, Clark AJ et al (2007) HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol 9:391–401CrossRefPubMed

25.

Efeyan A, Serrano M (2007) P53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6:1006–1010PubMed

26.

Puc J, Keniry M, Li HS et al (2005) Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7:193–204CrossRefPubMed

27.

Kim CJ, Lee JH, Song JW et al (2007) Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability. Eur J Surg Oncol 33:580–585CrossRefPubMed

28.

Bertoni F, Codegoni AM, Furlan D et al (1999) CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 26:176–180CrossRefPubMed

29.

Menoyo A, Alazzouzi H, Espin E et al (2001) Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 61:7727–7730PubMed

30.

Papp T, Niemetz A, Dosdahl N et al (2007) Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol Rep 17:135–140PubMed

31.

Kumar K, Rahman Q, Schipper H et al (2005) Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. Oncol Rep 14:743–750PubMed

32.

Haruki N, Saito H, Tatematsu Y et al (2000) Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 60:4689–4692PubMed

33.

Marsh A, Healey S, Lewis A et al (2007) Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Res Treat 105:377–389CrossRefPubMed

34.

Vahteristo P, Tamminen A, Karvinen P et al (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61:5718–5722PubMed

35.

Allinen M, Peri L, Kujala S et al (2002) Analysis of 11q21–24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 34:384–389CrossRefPubMed

36.

Hampton OA, Den Hollander P, Miller CA et al (2009) A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 19:167–177CrossRefPubMed

37.

Ameziane N, van den Ouweland AM, Adank MA et al (2009) Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat 118:651–653CrossRefPubMed

38.

Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388CrossRefPubMed

Title: Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families
Authors: Szilvia Solyom
Katri Pylkäs
Robert Winqvist
Publication date: 01-12-2010
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-010-9360-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer

Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits

Breast cancer susceptibility variants alter risk in familial ovarian cancer

Abstracts 3rd Biennial Meeting of InSiGHT (International Society for Gastrointestinal Hereditary Tumours)

Hereditary predisposition rather than environmental factor are likely to explain the familial link between uveal melanoma and other cancers

Report of the Combined Meeting of the International Society for Gastrointestinal Hereditary Tumours, the Human Variome Project and the National Cancer Institute Colon Cancer Family Registry, Duesseldorf, Germany, 24 June 2009

Keynote webinar | Spotlight on antibody–drug conjugates in cancer